You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Paraproteinemias

Showing 1 - 25 of 95
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance Trial in Washington (Daratumumab and

Not yet recruiting
  • Peripheral Neuropathy
  • Monoclonal Gammopathy of Undetermined Significance
  • Daratumumab and hyaluronidase-fihj
  • Washington, District of Columbia
    Lombardi Comprehensive Cancer Center, Georgetown University
Sep 14, 2023

Multiple Myeloma, Tumors, Tumor, Plasma Cell Trial (Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • +7 more
  • Belantamab Mafodotin-Blmf
  • +3 more
  • (no location specified)
Oct 11, 2022

Project in First-degree Relatives of Myeloma Patient - The

Recruiting
  • Multiple Myeloma
  • Monoclonal Gammopathy of Undetermined Significance
  • Sample of Blood
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 31, 2023

Monoclonal Gammopathy of Uncertain Significance Trial in Utrecht (Zanubrutinib Oral Product)

Not yet recruiting
  • Monoclonal Gammopathy of Uncertain Significance
  • Zanubrutinib Oral Product
  • Utrecht, Netherlands
    University Medical Center Utrecht
Jul 6, 2023

Multiple Myeloma, Multiple Myeloma in Relapse, Tumors Trial (Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • +8 more
  • Belantamab Mafodotin-Blmf
  • +3 more
  • (no location specified)
Oct 13, 2022

Monoclonal Gammopathies, Multiple Myeloma, M-protein Trial in Guangzhou (Observational studies, no intervention)

Recruiting
  • Monoclonal Gammopathies
  • +2 more
  • Observational studies, no intervention
  • Guangzhou, Guangdong, China
    Zhujiang Hospital of Southern Medical University
Jan 6, 2023

Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)

Not yet recruiting
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Smoldering Multiple Myeloma (SMM)
  • (no location specified)
Nov 17, 2023

Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma Trial in Cleveland (Multiple

Not yet recruiting
  • Multiple Myeloma
  • +2 more
  • Multiple Myeloma M-Protein Analysis
  • Multiple Myeloma Knowledge Questionnaires
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Apr 26, 2023

Multiple Myeloma, Tumors, Tumors, Plasma Cell Trial (Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • +7 more
  • Belantamab Mafodotin-Blmf
  • +3 more
  • (no location specified)
Mar 4, 2022

Quality of Life in Asymptomatic Monoclonal Gammopathies

Recruiting
  • Monoclonal Gammopathy of Undetermined Significance
  • Smoldering Plasma Cell Myeloma
  • Quality-of-Life Assessment
  • Questionnaire Administration
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Monoclonal Gammopathy Trial in New York, Philadelphia (Isatuximab)

Recruiting
  • Monoclonal Gammopathy
  • Boston, Massachusetts
  • +1 more
Nov 16, 2022

Lymphoma, Leukemia, Plasma Cell Dyscrasia Trial in San Francisco (Web Application)

Not yet recruiting
  • Lymphoma
  • +2 more
  • Web Application
  • San Francisco, California
    University of California, San Francisco
Oct 4, 2022

Immune System Diseases, Autoimmune Diseases, Inflammation Trial (observational cohort study)

Not yet recruiting
  • Immune System Diseases
  • +15 more
  • observational cohort study
  • (no location specified)
Jul 23, 2023

Study in Monoclonal Gammopathy of Undetermined Significance

Not yet recruiting
  • MGUS
    • Oxford, Oxfordshire, United Kingdom
      Secure Study
    Sep 9, 2022

    Two Biologically and Clinically Distinct Entities: Progressive

    Recruiting
    • Multiple Myeloma
    • +2 more
      • Miami, Florida
        University of Miami Hospitals
      Jun 7, 2022

      The Indiana Myeloma Registry

      Recruiting
      • Plasma Cell Dyscrasias
      • This is a non-interventional trial
      • Indianapolis, Indiana
        Indiana University Simon Cancer Center
      Mar 2, 2022

      Multiple Myeloma, Renal Impairment, Tumors, Plasma Cell Trial in Greece (Isatuximab, Bortezomib, Cyclophosphamide)

      Not yet recruiting
      • Multiple Myeloma
      • +7 more
      • Athens, Greece
      • +5 more
      Mar 28, 2022

      Multiple Myeloma, Renal Impairment, Tumors, Plasma Cell Trial in Greece (Isatuximab, Pomalidomide, Dexamethasone)

      Not yet recruiting
      • Multiple Myeloma
      • +7 more
      • Athens, Greece
      • +5 more
      Mar 17, 2022

      Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Cryoglobulinemic Vasculitis Trial (Isatuximab Injection)

      Not yet recruiting
      • Multiple Myeloma
      • +2 more
      • Isatuximab Injection
      • (no location specified)
      Oct 28, 2021

      Multicenter Case Series

      Recruiting
      • Monoclonal Gammopathy of Renal Significance
        • San Fermo Della Battaglia, Como, Italy
        • +7 more
        Jan 23, 2023

        Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)

        Active, not recruiting
        • Multiple Myeloma
        • +19 more
        • CYNK-001
        • Denver, Colorado
        • +8 more
        May 24, 2022

        Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM) Trial in Rochester (Curcumin plus Piperine)

        Recruiting
        • Prostate Cancer
        • +3 more
        • Curcumin plus Piperine
        • Rochester, New York
          University of Rochester
        Jun 17, 2022

        Multiple Myeloma, Monoclonal Gammopathy of Renal Significance Trial in United States (Cyclophosphamide, Bortezomib,

        Recruiting
        • Multiple Myeloma
        • Monoclonal Gammopathy of Renal Significance
        • Basking Ridge, New Jersey
        • +6 more
        Oct 16, 2023

        Acid Sphingomyelinase Deficiency Disease and Gaucher Disease in

        Recruiting
        • Gaucher Disease
        • Acid SphingoMyelinase Deficiency
          • Ponferrada, León, Spain
          • +11 more
          Aug 8, 2023

          Screening to Improve Survival in AL Amyloidosis

          Recruiting
          • Smoldering Multiple Myeloma
          • Monoclonal Gammopathy of Undetermined Significance
            • Orange, California
            • +5 more
            Nov 16, 2022